COD Research’s Post

The FDA has approved a new subcutaneous formulation of ocrelizumab (OCREVUS; Roche) for relapsing and primary progressive multiple sclerosis (MS). Marketed as Zunovo, this option adds more flexibility to the existing intravenous form by potentially reducing treatment time to just 55 minutes, providing additional convenience for patients and healthcare providers.   The approval is based on the OCARINA 2 study, which demonstrated similar efficacy between subcutaneous and IV ocrelizumab, with 99% of patients relapse-free at 24 weeks. Though subcutaneous administration led to more mild injection site reactions, the overall safety profile remained consistent.   Read More: https://lnkd.in/ezQpWiBF   #Neurology #MultipleSclerosis #MS

🧠We are delighted to share some highly cited papers on clinical neurology that were published in the Journal of Clinical Medicine in 2023.  📚 You can read them here: https://lnkd.in/dm6nXDD8 #clinical #medicine #neuorology #openaccess

Excited to share important information about the use of carbamazepine in treating epilepsy, trigeminal neuralgia, bipolar disorder, diabetic neuropathy, and acute alcohol withdrawal. This medication works by blocking neuronal channels and reducing glutamatergic transmission. However, it can have dose-related side effects and may interact with other medications. #Carbamazepine #Epilepsy #Neurology #Pharmacology #HealthcareAwareness

This beautifully performed study critically highlights the potential of methylene blue (MB) as an adjuvant therapy in septic shock, demonstrating significant reductions in vasopressor requirements and modulation of immune responses, despite the MB group presenting with more severe disease profiles.The non-blinded design, small sample size, and exclusion of COVID-19 patients restrict the study’s generalizability, and the absence of comprehensive data on long-term outcomes, cardiac output, and oxygen delivery limits definitive conclusions. Emphasis on continuous infusion for sustained results is an interesting finding ! #intensivecare #research #mrcp #mrcpuk #medicine #internalmedicine #neetpg #usmle #plab #fmge #neurology #doctors #MedicalResearch #EmergencyMedicine #ICU #TranslationalMedicine #Hemodynamics #PatientCare #SepsisManagement #InnovativeTherapies #RandomizedControlledTrial #HealthcareInnovation

Exciting news about 2024 PURE Neurology! Discover the latest trends in PAP/IRA, AI, FRM, product acquisitions, and more, along with insights into which companies received the highest ratings. How do you stack up against leading neuro companies like Biogen, Genentech, and Novartis? #PURE #Neurology #Pharma #Benchmarking

Having had family members suffer from Alzheimer's and knowing the struggle for patients and loved ones, it's great to see treatments coming to market! Considering the challenges with patient recruitment and clinical trials in the neurology space; commercial success will be hugely important to giving patients/healthcare providers options and lead to increased investment into Neurology studies across the board. #Alzheimers #Pharmaceuticals #Neurology

#OnlineFirst: Outcomes and predictors of intraprocedural rupture in patients with cerebral aneurysm Check out the Acta Neurochirurgica Article at: https://lnkd.in/dQigxyJT #neurosurgery #actaneuro #aneurysm

In the next few weeks, we would like to explain to you which road our patients would follow for an upcoming clinical trial. We call this “the process”. This week we’ll take a look at the third step: screening. During the screening period (and later on) we’ll do many examinations to verify if the patients are eligible for a specific clinical trial. And for that we have BIG NEWS. Because we can finally share that we are working together with a neurologist. From now on we can count on Dr. Merel Brems to carry out EEG, EMG, lumbar puncture and evoked potentials (SSEP, VEP, BAEP). We are looking forward to our coorporation. #process #screening #eligible #medical #medication #neurology #neurologist #EEG #EMG #lumbarpuncture #coorporation #protocol #clinical #trial #clinicaltrials #science #health #meclinas #mechelen

The 2024 PURE Neurology Report is Now Available! For the 5th year, 500 healthcare professionals ranked neurology patient support programs on key metrics like Awareness, Support Offerings, Patient Experience, Program Education, and more. With insights from 8,100 HCPs and 2,900 patients, PURE Engagement offers unmatched insights across various therapeutic areas. Want to know if you're Best-in-Class in 2024? Reach out now to find out! To learn more, see: https://lnkd.in/edZbfiUE #Neurology #Pharma #HCPs #PURE 

2024 PURE Neurology Report Launching Soon! For the 5th year, 500 healthcare professionals ranked neurology patient support programs on key metrics like Awareness, Support Offerings, Patient Experience, Program Education, and more. With insights from 8,100 HCPs and 2,900 patients, PURE Engagement offers unmatched insights across various therapeutic areas. Want to know if you're Best-in-Class in 2024? Reach out now to find out! To learn more, see: https://lnkd.in/edZbfiUE #Neurology #Pharma #HCPs #PURE